Literature DB >> 31841033

Calcitonin-negative medullary thyroid carcinoma: the 'triple-negative' phenotype.

D C Murphy1, S J Johnson2, S Aspinall2.   

Abstract

Calcitonin-negative medullary thyroid carcinoma is a rare, poorly understood primary neuroendocrine carcinoma of the thyroid characterised by classic medullary thyroid carcinoma morphology without raised serum calcitonin. A 24-year-old woman presented with a slow-growing, right-sided neck swelling. She underwent an ultrasound scan, cytopathological and histopathological examination, and tests for alternative diagnoses. The ultrasound showed a heterogeneous, hyperechoic nodule in the right thyroid lobe. Serum calcitonin was normal. Cytopathology and histopathology showed typical medullary thyroid carcinoma morphology but without calcitonin upon immunostaining and mRNA in situ hybridisation. A 'triple-negative' calcitonin-negative medullary thyroid carcinoma was diagnosed. A completion thyroidectomy with bilateral central lymph node dissection was performed. The patient remains well three-years post-surgery. When cytopathology suggests a medullary thyroid carcinoma, serum calcitonin, pro-calcitonin, carcinoembryonic antigen and calcitonin-gene-related peptide should be measured to identify cases of calcitonin-negative medullary thyroid carcinoma. They should also be measured post-treatment for monitoring purposes. This will aid future calcitonin-negative medullary thyroid carcinoma diagnoses and will inform prognostic stratification and influence treatment decisions.

Entities:  

Keywords:  Calcitonin-negative medullary thyroid carcinoma; Medullary thyroid carcinoma; Neuroendocrine; Thyroid; Thyroid cancer

Mesh:

Substances:

Year:  2019        PMID: 31841033      PMCID: PMC7027419          DOI: 10.1308/rcsann.2019.0153

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  4 in total

Review 1.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

Review 2.  Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature.

Authors:  Pierpaolo Trimboli; Luca Giovanella
Journal:  Clin Chem Lab Med       Date:  2015-09-01       Impact factor: 3.694

3.  Calcitonin and carcinoembryonic antigen as tumor markers in medullary thyroid carcinoma.

Authors:  R A DeLellis; A H Rule; I Spiler; L Nathanson; A H Tashjian; H J Wolfe
Journal:  Am J Clin Pathol       Date:  1978-10       Impact factor: 2.493

4.  Current management of medullary thyroid cancer.

Authors:  Rebecca S Sippel; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Oncologist       Date:  2008-05
  4 in total
  1 in total

1.  Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center.

Authors:  Sun Jung Kim; Hyeok Jun Yun; Su-Jin Shin; Yong Sang Lee; Hang-Seok Chang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-05       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.